|
A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART Clinical research trials and A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART. A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART clinical trial. Test subjects typically receive the most effective healthcare possible for their A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART  A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART
A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART
For Condition: HIV Infections
Status: Completed
Sponsor(s): Rockefeller University ,
Synopsis: To ascertain the effect of thalidomide on immune responses to vaccination with polyvalent pneumococcal polysaccharide vaccine and tetanus toxoid in HIV-infected patients; particularly, on markers of immune activation and parameters of specific, anti-HIV cellular immunity.
Details: Patients receive oral thalidomide in a blinded, placebo-controlled study. [AS PER AMENDMENT 11/25/98: This is a double-blind, placebo-controlled trial in which thalidomide or placebo is administered for 21 days. After the first week of therapy, patients receive immunizations with keyhole limpet hemocyanin and polyvalent pneumococcal vaccine. Study therapy is stopped for 2 weeks after the immunizations. Following the immunizations, detailed evaluations of the immune responses to the vaccines are conducted over the next 8 weeks.]
Eligibility:
Study Type: Interventional, Treatment, Placebo Control, Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - Documented HIV infection. - CD4+ cell count between 300 and 500 cells/mm3. - HIV-1 RNA < 500 by the branched-chain DNA assay (bDNA assay, Chiron) within 21 days of study entry [AS PER AMENDMENT 11/25/98: - Undetectable-plasma HIV titers (as defined by the FDA) by the branched-chain DNA test]. - Established B cell lines [deleted AS PER AMENDMENT 11/25/98]. - Response to at least one recall antigen in an in vitro assay of lymphocyte proliferative responses. - Life expectancy > 6 months [deleted AS PER AMENDMENT 11/25/98]. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Active opportunistic infection or HIV-related malignancy [HIV-related malignancy deleted AS PER AMENDMENT 11/25/98]. - Peripheral neuropathy of grade 2 or higher by Division of AIDS toxicity criteria. Concurrent Medication: Excluded: - Other investigational HIV-drugs. - Immunomodulatory or potentially immunomodulatory drugs, such as glucocorticoids, hematopoietins, interleukin-2, interferon, or pentoxifylline. Patients with the following prior conditions are excluded: History of serious hypersensitivity to tetanus toxoid or any of the vaccine components. Prior Medication: Excluded: - Previous immunization with pneumococcal polysaccharide vaccine [or, AS PER AMENDMENT 11/25/98, keyhole limpet hemocyanin vaccine]. - Tetanus toxoid booster within 5 years [deleted AS PER AMENDMENT 11/25/98]. - Other investigational HIV-drugs within 6 weeks of enrollment. - Immunomodulatory or potentially immunomodulatory drugs, such as glucocorticoids, hematopoietins, interleukin-2, interferon, or pentoxifylline within 6 weeks of enrollment. Risk Behavior: Excluded: Active drug or alcohol abuse. Required: Effective combination antiretroviral therapy including two nucleoside analog agents (ZDV, 3TC, ddI, ddC, or d4T) and nelfinavir or indinavir, for at least one month prior to study entry. [AS PER AMENDMENT 11/25/98: - On stable, effective, highly-active antiretroviral therapy with combinations of any FDA-approved anti-HIV drugs for at least 3 months prior to entry.]
Total Enrollment: 12
Location and Contact Information:
Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: 279A;
Study Start Date:
Record last reviewed: April 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002392
Other Hiv Infections Studies:
1. Comparing the Effects of Smoked and Oral Marijuana in Individuals with HIV/AIDS
2. A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection
3. Evaluating Immune Function Tests in People with HIV
4. A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)
5. Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection
Related Studies:
Other HIV Infections Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART
|
|
|
|
|
|
|
|
